Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

References

• Multiple Sclerosis International Federation (MSIF) [homepage on the Internet]Atlas of MS: Mapping Multiple Sclerosis Around the World2013 Available from: www.msif.org/atlasAccessed January 14, 2017
   Google Scholar
• DendrouCAFuggerLFrieseMAImmunopathology of multiple sclerosisNat Rev Immunol201515954555826250739
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• LipsyRJSchapiroRTProstkoCRCurrent and future directions in MS management: key considerations for managed care pharmacistsJ Manag Care Pharm2009159 suppl AS2S15 quiz S16–719877743
   PubMed Web of Science ®Google Scholar
• ColesAMultiple sclerosisPract Neurol20099211812619289565
   PubMedGoogle Scholar
• InduruwaIConstantinescuCSGranBFatigue in multiple sclerosis – a brief reviewJ Neurol Sci20123231–291522935407
   PubMed Web of Science ®Google Scholar
• ChalahMARiachiNAhdabRCreangeALefaucheurJPAyacheSSFatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulationFront Cell Neurosci2015946026648845
   PubMed Web of Science ®Google Scholar
• PennerIKEvaluation of cognition and fatigue in multiple sclerosis: daily practice and future directionsActa Neurol Scand2016134suppl 200192327580902
   PubMed Web of Science ®Google Scholar
• RaoSMLeoGJBernardinLUnverzagtFCognitive dysfunction in multiple sclerosis. I. frequency, patterns, and predictionNeurology19914156856912027484
   PubMed Web of Science ®Google Scholar
• RoccaMAAmatoMPDe StefanoNClinical and imaging assessment of cognitive dysfunction in multiple sclerosisLancet Neurol201514330231725662900
   PubMed Web of Science ®Google Scholar
• MarrieRAReingoldSCohenJThe incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic reviewMult Scler201521330531725583845
   PubMed Web of Science ®Google Scholar
• AnnibaliVMechelliRRomanoSIFN-beta and multiple sclerosis: from etiology to therapy and backCytokine Growth Factor Rev201526222122825466632
   PubMed Web of Science ®Google Scholar
• EbersGInteractions of environment and genes in multiple sclerosisJ Neurol Sci20133341–216116324007873
   PubMed Web of Science ®Google Scholar
• GolanDStaun-RamEMillerAShifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specificCurr Opin Neurol201629335436127070218
   PubMed Web of Science ®Google Scholar
• CarlsonRJDoucetteJRKnoxKNazaraliAJPharmacogenomics of interferon-beta in multiple sclerosis: what has been accomplished and how can we ensure future progress?Cytokine Growth Factor Rev201526224926125524087
   PubMed Web of Science ®Google Scholar
• LublinFDReingoldSCCohenJADefining the clinical course of multiple sclerosis: the 2013 revisionsNeurology201483327828624871874
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosisAnn Neurol200150112112711456302
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSNatural history of multiple sclerosis: a unifying conceptBrain2006129pt 360661616415308
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
   PubMed Web of Science ®Google Scholar
• FreedmanMSSelchenDArnoldDLTreatment optimization in MS: Canadian MS working group updated recommendationsCan J Neurol Sci201340330732323603165
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multi-center, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• PRISMS Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• CalabresiPAKieseierBCArnoldDLPegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyLancet Neurol201413765766524794721
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study groupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPComiGOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Neurol201413324725624461574
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• DurelliLBarberoPClericoMINCOMIN Trial Study GroupA randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisNeurology200667122264 author reply 2264–517190964
   PubMed Web of Science ®Google Scholar
• SchwidSRPanitchHSFull results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosisClin Ther20072992031204818035202
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
   PubMed Web of Science ®Google Scholar
• VermerschPCzlonkowskaAGrimaldiLMTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMult Scler201420670571624126064
   PubMed Web of Science ®Google Scholar
• RoskellNSZimovetzEARycroftCEEckertBJTyasDAAnnualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimodCurr Med Res Opin201228576778022462530
   PubMed Web of Science ®Google Scholar
• TolleyKHutchinsonMYouXA network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosisPLoS One2015106e012796026039748
   PubMed Web of Science ®Google Scholar
• TramacereIDel GiovaneCSalantiGD’AmicoRFilippiniGImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisCochrane Database Syst Rev20159CD011381
   Google Scholar
• CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJFoxEVladicAAlemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesLancet Neurol201110433834821397567
   PubMed Web of Science ®Google Scholar
• BakerDPPepinskyRBBrickelmaierMPEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosisJ Interferon Cytokine Res2010301077778520836711
   PubMed Web of Science ®Google Scholar
• BhargavaPNewsomeSDAn update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosisTher Adv Neurol Disord20169648349027800024
   PubMed Web of Science ®Google Scholar
• CoccoEMarrosuMGProfile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisTher Clin Risk Manag20151175976626056458
   PubMed Web of Science ®Google Scholar
• HowleyAKremenchutzkyMPegylated interferons: a nurses’ review of a novel multiple sclerosis therapyJ Neurosci Nurs2014462889624556656
   PubMed Web of Science ®Google Scholar
• HoySMPeginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosisCNS Drugs201529217117925666445
   PubMed Web of Science ®Google Scholar
• KieseierBCCalabresiPAPEGylation of interferon-beta-1a: a promising strategy in multiple sclerosisCNS Drugs201226320521422201341
   PubMed Web of Science ®Google Scholar
• ReussRPEGylated interferon beta-1a in the treatment of multiple sclerosis – an updateBiologics2013713113823807836
   PubMedGoogle Scholar
• NallarSCKalvakolanuDVInterferons, signal transduction pathways, and the central nervous systemJ Interferon Cytokine Res201434855957625084173
   PubMed Web of Science ®Google Scholar
• SeveraMRizzoFGiacominiESalvettiMCocciaEMIFN-beta and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networksCytokine Growth Factor Rev201526222923925498525
   PubMed Web of Science ®Google Scholar
• BuzzardKABroadleySAButzkuevenHWhat do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Int J Mol Sci20121310126651270923202920
   PubMed Web of Science ®Google Scholar
• JacobsLJohnsonKPA brief history of the use of interferons as treatment of multiple sclerosisArch Neurol19945112124512527986181
   PubMedGoogle Scholar
• RunkelLMeierWPepinskyRBStructural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)Pharm Res19981546416499587963
   PubMed Web of Science ®Google Scholar
• KapposLKuhleJMultanenJFactors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15J Neurol Neurosurg Psychiatry201586111202120726374702
   PubMed Web of Science ®Google Scholar
• GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trialNeurology201278171315132222496198
   PubMed Web of Science ®Google Scholar
• ShiraniAZhaoYKarimMEAssociation between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosisJAMA2012308324725622797642
   PubMed Web of Science ®Google Scholar
• GoodinDSRederATCutterGTreatment with interferon beta for multiple sclerosisJAMA2012308161627 author reply 1627–823093155
   PubMed Web of Science ®Google Scholar
• GreenbergBMBalcerLCalabresiPAInterferon beta use and disability prevention in relapsing-remitting multiple sclerosisJAMA Neurol201370224825123530268
   PubMed Web of Science ®Google Scholar
• DerfussTKapposLEvaluating the potential benefit of interferon treatment in multiple sclerosisJAMA2012308329029122797647
   PubMed Web of Science ®Google Scholar
• HegenHAuerMDeisenhammerFPharmacokinetic considerations in the treatment of multiple sclerosis with interferon-betaExpert Opin Drug Metab Toxicol201511121803181926419922
   PubMed Web of Science ®Google Scholar
• FletcherJMLalorSJSweeneyCMTubridyNMillsKHT cells in multiple sclerosis and experimental autoimmune encephalomyelitisClin Exp Immunol2010162111120682002
   PubMed Web of Science ®Google Scholar
• GuoBChangEYChengGThe type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in miceJ Clin Invest200811851680169018382764
   PubMed Web of Science ®Google Scholar
• DurelliLContiLClericoMT-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-betaAnn Neurol200965549950919475668
   PubMed Web of Science ®Google Scholar
• ZhangLYuanSChengGGuoBType I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammationPLoS One2011612e2843222163016
   PubMed Web of Science ®Google Scholar
• KozovskaMEHongJZangYCInterferon beta induces T-helper 2 immune deviation in MSNeurology19995381692169710563614
   PubMed Web of Science ®Google Scholar
• RamgolamVSShaYJinJZhangXMarkovic-PleseSIFN-beta inhibits human Th17 cell differentiationJ Immunol200918385418542719783688
   PubMed Web of Science ®Google Scholar
• de AndresCAristimunoCde Las HerasVInterferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosisJ Neuroimmunol20071821–220421117157927
   PubMed Web of Science ®Google Scholar
• RamgolamVSShaYMarcusKLB cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosisJ Immunol201118674518452621368231
   PubMed Web of Science ®Google Scholar
• RizzoFGiacominiEMechelliRInterferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosisImmunol Cell Biol201694988689427265253
   PubMed Web of Science ®Google Scholar
• SarasteMIrjalaHAirasLExpansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-betaNeurol Sci200728312112617603762
   PubMed Web of Science ®Google Scholar
• ShinoharaMLKimJHGarciaVACantorHEngagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontinImmunity2008291687818619869
   PubMed Web of Science ®Google Scholar
• MirandolaSRHallalDEFariasASInterferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosisInt Immunopharmacol200997–882483019289181
   PubMed Web of Science ®Google Scholar
• LiuZPelfreyCMCotleurALeeJCRudickRAImmunomodulatory effects of interferon beta-1a in multiple sclerosisJ Neuroimmunol20011121–215316211108944
   PubMed Web of Science ®Google Scholar
• KrakauerMSorensenPKhademiMOlssonTSellebjergFIncreased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expressionMult Scler200814562263018424480
   PubMed Web of Science ®Google Scholar
• OzenciVKouwenhovenMHuangYMMultiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatmentScand J Immunol199949555456110320650
   PubMed Web of Science ®Google Scholar
• CalabresiPATranquillLRMcFarlandHFCowanEPCytokine gene expression in cells derived from CSF of multiple sclerosis patientsJ Neuroimmunol1998891–21982059726843
   PubMed Web of Science ®Google Scholar
• ChenMChenGNieHRegulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MSEur J Immunol20093992525253619670379
   PubMed Web of Science ®Google Scholar
• BernalFEliasBHartungHPKieseierBCRegulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patientsMult Scler200915672172719383643
   PubMed Web of Science ®Google Scholar
• BozCOzmenogluMVeliogluSMatrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon betaClin Neurol Neurosurg2006108212412816412833
   PubMed Web of Science ®Google Scholar
• AvolioCFilippiMTortorellaCSerum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatmentMult Scler200511444144616042227
   PubMed Web of Science ®Google Scholar
• CalabresiPAPelfreyCMTranquillLRMaloniHMcFarlandHFVLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon betaNeurology1997494111111169339698
   PubMed Web of Science ®Google Scholar
• MuraroPALeistTBielekovaBMcFarlandHFVLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosisJ Neuroimmunol20001111–218619411063837
   PubMed Web of Science ®Google Scholar
• MuraroPALiberatiLBonanniLDecreased integrin gene expression in patients with MS responding to interferon-beta treatmentJ Neuroimmunol20041501–212313115081256
   PubMed Web of Science ®Google Scholar
• BiernackiKAntelJPBlainMNarayananSArnoldDLPratAInterferon beta promotes nerve growth factor secretion early in the course of multiple sclerosisArch Neurol200562456356815824253
   PubMedGoogle Scholar
• CaggiulaMBatocchiAPFrisulloGNeurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapyClin Immunol20061181778216275091
   PubMed Web of Science ®Google Scholar
• LindquistSHassingerSLindquistJASailerMThe balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatmentMult Scler201117785186621561957
   PubMed Web of Science ®Google Scholar
• LiDKPatyDWMagnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosisAnn Neurol199946219720610443885
   PubMed Web of Science ®Google Scholar
• PRISMS Study GroupPRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MSNeurology200156121628163611425926
   PubMed Web of Science ®Google Scholar
• UitdehaagBConstantinescuCCornelissePImpact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyTher Adv Neurol Disord20114131421339904
   PubMedGoogle Scholar
• GoldRRieckmannPChangPAbdallaJPRISMS Study GroupThe long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS studyEur J Neurol200512864965616053475
   PubMed Web of Science ®Google Scholar
• SiegertRJAbernethyDADepression in multiple sclerosis: a reviewJ Neurol Neurosurg Psychiatry200576446947515774430
   PubMed Web of Science ®Google Scholar
• PattenSBFrancisGMetzLMLopez-BresnahanMChangPCurtinFThe relationship between depression and interferon beta-1a therapy in patients with multiple sclerosisMult Scler200511217518115794391
   PubMed Web of Science ®Google Scholar
• SchipplingSO’ConnorPKnappertzVIncidence and course of depression in multiple sclerosis in the multinational BEYOND trialJ Neurol201626371418142627177997
   PubMed Web of Science ®Google Scholar
• BertolottoAMalucchiSSalaADifferential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratoryJ Neurol Neurosurg Psychiatry200273214815312122172
   PubMed Web of Science ®Google Scholar
• BozCOgerJGibbsEGrossbergSENeurologists of the UBC MS ClinicReduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based studyMult Scler20071391127113717967840
   PubMed Web of Science ®Google Scholar
• HegenHSchleiserMGneissCPersistency of neutralizing antibodies depends on titer and interferon-beta preparationMult Scler201218561061522013146
   PubMed Web of Science ®Google Scholar
• PachnerARCadavidDWolanskyLSkurnickJEffect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME studyNeurology200973181485149219884576
   PubMed Web of Science ®Google Scholar
• PachnerARWarthJDPaceAGoelzSINSIGHT investigatorsEffect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT studyNeurology200973181493150019884577
   PubMed Web of Science ®Google Scholar
• PaolicelliDD’OnghiaMPellegriniFThe impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing studyJ Neurol201326061562156823417273
   PubMed Web of Science ®Google Scholar
• FrancisGSRiceGPAlsopJCPRISMS Study GroupInterferon beta-1a in MS: results following development of neutralizing antibodies in PRISMSNeurology2005651485516009884
   PubMed Web of Science ®Google Scholar
• PetkauAJWhiteRAEbersGCLongitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisMult Scler200410212613815124756
   PubMed Web of Science ®Google Scholar
• ReynoldsMWStephenRSeamanCRajagopalanKPersistence and adherence to disease modifying drugs among patients with multiple sclerosisCurr Med Res Opin201026366367420070144
   PubMed Web of Science ®Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
   PubMed Web of Science ®Google Scholar
• TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
   PubMed Web of Science ®Google Scholar
• WongJGomesTMamdaniMMannoMO’ConnorPWAdherence to multiple sclerosis disease-modifying therapies in Ontario is lowCan J Neurol Sci201138342943321515501
   PubMed Web of Science ®Google Scholar
• EvansCMarrieRAZhuFAdherence and persistence to drug therapies for multiple sclerosis: a population-based studyMult Scler Relat Disord20168788527456879
   PubMed Web of Science ®Google Scholar
• LafataJECerghetMDobieEMeasuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosisJ Am Pharm Assoc (2003)200848675275719019804
   PubMed Web of Science ®Google Scholar
• HansenKSchusselKKiebleMAdherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort studyPLoS One2015107e013327926214805
   PubMed Web of Science ®Google Scholar
• GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762
   PubMed Web of Science ®Google Scholar
• RinonABuchMHolleyDVerdunEThe MS choices survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosisPatient Prefer Adherence2011562964322259240
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler2005111465015732266
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• GirouardNTheoretGManagement strategies for improving the tolerability of interferons in the treatment of multiple sclerosisCan J Neurosci Nurs2008304182519146204
   PubMedGoogle Scholar
• BayasAImproving adherence to injectable disease-modifying drugs in multiple sclerosisExpert Opin Drug Deliv201310328528723339371
   PubMed Web of Science ®Google Scholar
• FishburnCSThe pharmacology of PEGylation: balancing PD with PK to generate novel therapeuticsJ Pharm Sci200897104167418318200508
   PubMed Web of Science ®Google Scholar
• TurecekPLBossardMJSchoetensFIvensIAPEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugsJ Pharm Sci2016105246047526869412
   PubMed Web of Science ®Google Scholar
• AghemoARumiMGColomboMPegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis CNat Rev Gastroenterol Hepatol20107948549420644567
   PubMed Web of Science ®Google Scholar
• HuXMillerLRichmanSA novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyJ Clin Pharmacol201252679880821680782
   PubMed Web of Science ®Google Scholar
• KieseierBCArnoldDLBalcerLJPeginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEMult Scler20152181025103525432952
   PubMed Web of Science ®Google Scholar
• ArnoldDLCalabresiPAKieseierBCEffect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosisBMC Neurol20141424025551571
   PubMed Web of Science ®Google Scholar
• NewsomeSDKieseierBCArnoldDLSubgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosisJ Neurol201626391778178727314959
   PubMed Web of Science ®Google Scholar
• KremenchutzkyMLiuSCuiYHungSSeddighzadehAEvilevitchVLong-term safety and tolerability of peginterferon beta-1a: interim analysis from ATTAIN, a phase 3 extension studyNeurology20158414S4.002
   Google Scholar
• WhiteJTNewsomeSDKieseierBCIncidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trialTher Adv Neurol Disord20169423924927366230
   PubMed Web of Science ®Google Scholar
• HalperJCentonzeDNewsomeSDManagement strategies for flu-like symptoms and injection-site reactions associated with peginterferon beta-1a: obtaining recommendations using the delphi techniqueInt J MS Care201618421121827551246
   PubMedGoogle Scholar
• HuXShangSNestorovICOMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjectsBr J Clin Pharmacol201682238038827060836
   PubMed Web of Science ®Google Scholar
• HernandezLGuoSKinterEFayMCost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the united statesJ Med Econ201619768469526947984
   PubMed Web of Science ®Google Scholar
• MoriFKusayanagiHButtariFEarly treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosisFunct Neurol201227316316823402677
   PubMed Web of Science ®Google Scholar
• PattiFMorraVBAmatoMPSubcutaneous interferon beta-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS studyPLoS One201388e7411124137499
   PubMed Web of Science ®Google Scholar
• CinarBPKosehasanogullariGYigitPOzakbasSCognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS batteryNeurol Sci Epub20161124
   Google Scholar